Weight-Loss Drugs Show Promise in Reducing Cancer Risk, Though Questions Remain

One in eight American adults now takes a GLP-1 receptor agonist—drugs like Ozempic and Wegovy designed to help people lose weight. Researchers are beginning to notice something unexpected: these medications may also reduce the risk of developing certain cancers, or prevent them from returning after treatment. The findings come from observational studies rather than the more rigorous clinical trials that typically establish medical breakthroughs, but the consistency of the signal has made cancer specialists take notice. At a recent gathering of America's leading oncologists, the conversation centered on a single emerging hypothesis: these weight-loss drugs appear to fight cancer in ways that go beyond what simple weight loss alone would predict.

Dr. Neil Iyengar, who directs breast oncology and cancer survivorship at Emory University's Winship Cancer Institute, has spent years studying the link between obesity and malignancy. The connection is well-established. Obesity is tied to the development of at least thirteen different cancers, possibly twenty. For decades, researchers have known that reversing obesity could theoretically reduce cancer risk, but the tools to achieve meaningful weight loss have been limited—until now. The GLP-1 drugs represent a genuine shift in what's possible. They can induce weight loss of fifteen to twenty percent or more, comparable to what bariatric surgery achieves.

The observational data pointing toward cancer prevention is striking. A University of Pennsylvania analysis found that women between forty-five and eighty who took these drugs were roughly thirty percent less likely to develop breast cancer than those who did not. Another study tracked patients with seven types of early-stage cancer and found that GLP-1 use significantly reduced the risk of spread in four of them: lung, breast, colon, and liver cancers. When Iyengar considers these numbers, he attributes the effect primarily to weight loss itself. Prior research on diet and exercise interventions, which produce smaller weight reductions, still showed measurable reductions in cancer risk. Bariatric surgery studies demonstrate a clear pattern: the more weight someone loses, the lower their cancer risk becomes. The GLP-1 drugs simply achieve weight loss at a scale that makes the protective effect visible in large datasets.

But Iyengar is careful to note that weight loss is not the only mechanism at play. These drugs carry anti-inflammatory properties, and researchers are beginning to understand possible immune-related effects as well. Still, the weight loss appears to be the primary driver. This distinction matters because it suggests that the cancer-prevention benefit is not some unexpected side effect of the medication itself, but rather a consequence of the profound metabolic change the drugs enable.

The potential implications are enormous. One in seven cancer deaths among men and one in six among women are linked to obesity. If GLP-1 drugs can meaningfully reduce obesity at a population level—and early evidence suggests they can—the global burden of obesity-related cancers could shift dramatically. Yet Iyengar emphasizes caution. The data on how these drugs interact with different cancer types remains mixed. More critically, no one yet knows how GLP-1s might interact with active cancer treatments like chemotherapy or immunotherapy. They could potentially worsen side effects or reduce the effectiveness of immune-based therapies.

This uncertainty shapes his clinical recommendations. For cancer survivors who have completed treatment and are struggling with obesity, a conversation with their oncologist about GLP-1 use could be worthwhile. The drugs might help them lose weight and reduce the risk of recurrence. But for patients currently undergoing chemotherapy or immunotherapy, Iyengar advises against it until more data exists. The stakes are too high to experiment. What looks promising in observational studies must be tested in prospective, rigorous trials before oncologists can confidently recommend these drugs to their most vulnerable patients. The field stands at a threshold—excited by possibility, but disciplined by the knowledge that preliminary findings and clinical reality are not the same thing.